The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy?

Table of Contents

This article in an erratum and refers to S. G. Gray et al. The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy? in Hormone Metab Res, Issue 11/12, 2003; 35: 857 - 871 .

Figure [1] was printed in black and white but should have been printed in colours as shown below:

Fig. 1 Receptor Tyrosine Kinases. This figure is adapted from [100], updated with information compiled from multiple references and various databases such as Pfam. We found that all published figures on the domain organisation of RTKs contain inaccuracies and discrepancies, which we have tried to correct and reconcile. We would be grateful if any remaining error or omission was reported to us. The RTKs in bold type have been implicated in human malignancies.
1 ErbB1 (EGFR), ErbB2, ErbB3, ErbB4 (ErbB3 is a dead kinase)
2 INSR, IGF-IR, IRRR
3 PDGFRα, PDGFRβ, CSF1R (c-Kit), Flk2
4 VEGFR (Flt1), Flt4, KDR
5 FGFR 1- 4
6 TRKA, TRKB, TRKC
7 Ror1, Ror2
8 MusK
9 Met (HGFR/scatter factor receptor), Ron, Sea
10 Axl, Mer, Eyk, Tyro3, Nyk
11 Tie, Tek (Tie2)
12 Eph A1- 8, B1- 6
13 Ret
14 Ryk
15 DDR1, DDR2
16 Ros
17 AATYK
18 ALK, LTK
19 PTK7, KLG